TIDMSNG
RNS Number : 5144D
Synairgen plc
22 June 2023
Synairgen plc
('Synairgen' or the 'Company')
Grant of Options
Southampton, UK - 22 June 2023: Synairgen plc (LSE: SNG), the
respiratory company developing SNG001, an investigational
formulation for inhalation containing the broad-spectrum antiviral
protein interferon beta, announces that on 21 June 2023 the Board
of Synairgen granted options ('Options') over 6,132,718 ordinary
shares of one pence each in the capital of the Company ('Ordinary
Shares') at an exercise price of one pence per Ordinary Share. The
Options represent in aggregate 3.05 per cent. of the Company's
issued share capital.
Following this grant, Synairgen has 18,119,156 options in issue,
representing 9.00 per cent. of the Company's issued share
capital.
Certain Options were issued to Directors of the Company and
Persons Discharging Managerial Responsibilities ('PDMR'):
Percentage
Options holding of
issued 21 Total Ordinary Total fully diluted
June 2023 options shares interest share capital
Directors
---------- ---------- --------- ---------- ---------------
Richard Marsden(1) 496,000 2,819,178 995,771 3,814,949 1.74%
---------- ---------- --------- ---------- ---------------
Dr. Phillip
Monk 480,000 2,159,771 423,934 2,583,705 1.18%
---------- ---------- --------- ---------- ---------------
John Ward 480,000 2,259,140 734,092 2,993,232 1.36%
---------- ---------- --------- ---------- ---------------
PDMRs
---------- ---------- --------- ---------- ---------------
Jody Brookes 480,000 1,323,590 - 1,323,590 0.60%
---------- ---------- --------- ---------- ---------------
Richard Francis 480,000 1,108,636 - 1,108,636 0.51%
---------- ---------- --------- ---------- ---------------
Richard Hennings 480,000 1,237,568 - 1,237,568 0.56%
---------- ---------- --------- ---------- ---------------
Gareth Walters 480,000 1,115,779 - 1,115,779 0.51%
---------- ---------- --------- ---------- ---------------
1. Richard Marsden's shareholding includes 184,821 shares held in his pension plan.
The Options are issued under the Company's Long Term Incentive
Plan and are exercisable up to 20 June 2033, subject to the
achievement of appropriate performance criteria which match the
criteria for the 2022 award as set out on page 23 of the 2022
annual report.
The information contained within this announcement is deemed to
constitute inside information as stipulated under the retained EU
law version of the Market Abuse Regulation (EU) No. 596/2014 (the
"UK MAR") which is part of UK law by virtue of the European Union
(Withdrawal) Act 2018.
For further enquiries, please contact:
Synairgen plc
Media@synairgen.com
Tel: + 44 (0) 23 8051 2800
finnCap (NOMAD and Joint Broker)
Geoff Nash, Charlie Beeson (Corporate Finance)
Alice Lane, Sunil de Silva (ECM)
Tel: + 44 (0) 20 7220 0500
Numis Securities Limited (Joint Broker)
Freddie Barnfield, Duncan Monteith
Tel: + 44 (0) 20 7260 1000
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott, Namrata Taak, Lucy Featherstone
cscsynairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
MKC STRATEGIES, LLC (US Media Relations)
Mary Conway
MConway@MKCStrategies.com
Tel: +1 516-606-6545
Notes for Editors
About Synairgen
Synairgen is a UK-based respiratory company focused on drug
discovery, development and commercialisation. The Company's primary
focus is developing SNG001 (inhaled interferon beta) for the
treatment of severe viral lung infections, including COVID-19, as
potentially the first host-targeted, broad-spectrum antiviral
treatment delivered directly into the lungs. SNG001 has been
granted Fast Track status from the US Food and Drug Administration
(FDA). Founded by University of Southampton Professors Sir Stephen
Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is
quoted on AIM (LSE: SNG). For more information about Synairgen,
please see www.synairgen.com .
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated
with them ('PCA')
a) Name Richard Marsden
2. Reason for notification
a) Position / status Chief Executive Officer
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial instrument Options over ordinary shares of 1p each
Identification code
GB00B0381Z20
b) Nature of the transaction Award of Options under the Company's share plans
c) Price(s) and volume(s) 496,000 Options awarded
Exercise price of one pence
d) Aggregated information n/a
Aggregated volume Price
e) Date of the transaction 21 June 2023
f) Place of the transaction Outside a trading venue
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated
with them ('PCA')
a) Name Dr Phillip Monk
2. Reason for notification
a) Position / status Chief Scientific Officer
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial instrument Options over ordinary shares of 1p each
Identification code
GB00B0381Z20
b) Nature of the transaction Award of Options under the Company's share plans
c) Price(s) and volume(s) 480,000 Options awarded
Exercise price of one pence
d) Aggregated information n/a
Aggregated volume Price
e) Date of the transaction 21 June 2023
f) Place of the transaction Outside a trading venue
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated
with them ('PCA')
a) Name John Ward
2. Reason for notification
a) Position / status Chief Financial Officer
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial instrument Options over ordinary shares of 1p each
Identification code
GB00B0381Z20
b) Nature of the transaction Award of Options under the Company's share plans
c) Price(s) and volume(s) 480,000 Options awarded
Exercise price of one pence
d) Aggregated information n/a
Aggregated volume Price
e) Date of the transaction 21 June 2023
f) Place of the transaction Outside a trading venue
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated
with them ('PCA')
a) Name Jody Brookes
2. Reason for notification
a) Position / status Head of Clinical Operations
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial instrument Options over ordinary shares of 1p each
Identification code
GB00B0381Z20
b) Nature of the transaction Award of Options under the Company's share plans
c) Price(s) and volume(s) 480,000 Options awarded
Exercise price of one pence
d) Aggregated information n/a
Aggregated volume Price
e) Date of the transaction 21 June 2023
f) Place of the transaction Outside a trading venue
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated
with them ('PCA')
a) Name Richard Francis
2. Reason for notification
a) Position / status Head of CMC and Quality
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial instrument Options over ordinary shares of 1p each
Identification code
GB00B0381Z20
b) Nature of the transaction Award of Options under the Company's share plans
c) Price(s) and volume(s) 480,000 Options awarded
Exercise price of one pence
d) Aggregated information n/a
Aggregated volume Price
e) Date of the transaction 21 June 2023
f) Place of the transaction Outside a trading venue
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated
with them ('PCA')
a) Name Richard Hennings
2. Reason for notification
a) Position / status Chief Commercial Officer
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial instrument Options over ordinary shares of 1p each
Identification code
GB00B0381Z20
b) Nature of the transaction Award of Options under the Company's share plans
c) Price(s) and volume(s) 480,000 Options awarded
Exercise price of one pence
d) Aggregated information n/a
Aggregated volume Price
e) Date of the transaction 21 June 2023
f) Place of the transaction Outside a trading venue
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated
with them ('PCA')
a) Name Gareth Walters
2. Reason for notification
a) Position / status Chief Regulatory Officer
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial instrument Options over ordinary shares of 1p each
Identification code
GB00B0381Z20
b) Nature of the transaction Award of Options under the Company's share plans
c) Price(s) and volume(s) 480,000 Options awarded
Exercise price of one pence
d) Aggregated information n/a
Aggregated volume Price
e) Date of the transaction 21 June 2023
f) Place of the transaction Outside a trading venue
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEAEKFAFNDEAA
(END) Dow Jones Newswires
June 22, 2023 02:00 ET (06:00 GMT)
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
